Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor Argen		ita, et al.		
Art Unit		3733		
Examiner Name PHIL		OGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

					U.S.I	PATENTS			Remove	
Examiner Cite Initial* No		Patent Number	ktent Number Kind Code ¹				Relev		ges,Columns,Lines where elevant Passages or Relevant gures Appear	
	1									
If you wis	h to a	l dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove	
			Kind Code ¹	Gind Publication Code ¹ Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publi		,		,		d button		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or v	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т.
	1									
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc), o				Τs

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Filing Date First Named Inventor Argent Art Unit		10647068		
			2003-08-22		
			nta, et al.		
			3733		
			OGENE, PEDRO		
	Attack Desirat North		0404 D02077UC4		

1	October 6, 2005. BS-196	
2	KCI v. BlueSky, Order Adopting the Parties' Stipulated Claim Term Constructions. BS-197	
3	KCI v. BlueSky, Defendant Bluesky Medical Croup Inc. and Richard Weston's Reply to Plaintiffs Opposition to Defendant Bluesky Medical Croup Inc. and Richard Weston's Motions for Partial Summary Judgment dated September 22. 2005. ISS-198	
4	KCI v. Bluesky, Order Granting Plaintiffs' unopposed motion to supplement the record for its response to Bluesky's Motion for Partial Summary Judgment dated October 13, 2005. BS-200	
5	KCI v. Bluesky, Order granting Medela, Inc. and Medela AG's unopposed Motion to Extend Deadlines for Markman Briefing dated Odober 13, 2005. BS-201	
6	KCl v. Bluesky, Plaintiff's Unopposed Motion to Supplement the record in support of their response to Bluesky's motion for partial summary judgment on counts 12, 13, and 15 dated October 10, 2005 (With Exh.). BS-202	
7	KCI v. BlueSky, Defendants' Opening Brief Regarding Claim Construction for The '081 Patent and Certain Claims of the '643 Patent dated October 5, 2005. BS-203	
8	KCI v. BlueSky, Jont Claim Construction and Prehearing Statement dated September 16, 2005. BS-204	
9	KCI v. BlueSky, Defendant Bluesky Medical Circup Incorporated's and Richard Weston's Motion for Summary Judgment on the '643 Patent dated August 10, 2005. BS-205	
10	KCl v BlueSky, Defendant Bluesky Medical Group Incorporated's and Richard Weston's Motion for Partial Summary Judgment on the '880 Patent dated August 10, 2005. BS-206	
11	KCI v. BlueSky, BlueSky Medical Croup Inc. and Richard Weston's motion to exclude certain expert testmony dated April 21, 2006 BS-208	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10647068		
	Filing Date		2003-08-22		
	First Named Inventor Argen		ta, et al.		
	Art Unit		3733		
			OGENE, PEDRO		
			0404 D02077UC4		

12	Orgill and Wilson C. Hayes, dated April 21, 2006 BS-209	
13	KCI v. BlueSky, Plantiff's motion to exclude opinions of Vincent Pizziconi dated April 21, 2006 BS-210	
14	KCI v. BlueSky, Plantiff's motion to exclude certain opinions of Michael O'Neil dated April 21, 2006 BS-211	
15	KCI v. BlueSky, Medela's response to plantiff's motion to exclude opinions of Harriet Hopf with Exhibits dated April 28, 2006. BS-212	
16	KCI v. BlueSky, Medela's response to plaintiff's motion to exclude opinions of Michael O'Neil and motion to exclude opinions of John T. Goolikasian with Exhibits dated April 28, 2006 BS-213	
17	KCI v. BlueSky. Medela's response to plaintiff's motion to exclude opinions of James Spahn dated April 28,2006 BS-214	
18	KCI v. BlueSky, Plantiff's response to Medela's motion to exclude proposed trial testimony of Louis C. Argenta, Dennis P. Orgill, and Wilson C. Hayes, dated May 1, 2006 BS-215	
19	KCI v. BlueSty, Medela's Renewed Molson for Judgement as a Matter of Law, or , in the alternative , a New Trial, on Patent invalidity, dated September 13,2006. BS-216	
20	KCI v. BlueSky, Medela's Motion for a New Trial on Unenforceability, dated September 13, 2006 BS-217	
21	Claim Chart of Asserted Claims of U.S. Patent 5,636,643 to Argenta, 3 pages. BS-218	
22	Claim invalidity Analysis of U.S. Patent 5,636,643 to Argenta, et at., 34 pages, March 2004 BS-219	

	23	KCl v. BlueSky, Letter dated December 9, 2005 from the Honorable Royal Ferguson to attorneys in KCl v. BlueSky regarding datim construction BS-220	
	24	KCI v, BlueSky, Letter from Valery Gilevich, M.D. to Kirt S. O'Nelll, dated May 28, 2006 concerning review of English translation of Russian article BS-221	
	25	KCI v. BlueSky, Second Amended Order Construing Patent '643 and '061 Claim Terms dated June 29, 2006 BS-222	
	26	KCI v. BlueSky, Amended answer to third amended complaint, additional defenses, second amended counterclaims and jury demand of Medela, inc. dated July 12, 2005. BS-223	
	27	KCI v. BlueSky, Additional supplemental discovery, website printouts dated September 6, 2005. BS-224	
	28		
	29		
	30		
	31		
	32		
	33		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) This is the state of th

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor Argen		ita, et al.		
Art Unit		3733		
Examiner Name	PHIL	OGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

34	

If you wish to add additional non-patent literature document citation information please click the Add button Add

FYAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patient Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the holietier code (WIPO Standard ST.3). ² For disparsee patient colourests, by machine of the year of the Preprint must proceed the sear number of the Patient Colourest, and colourests, be noticed in on the year of the Proprint must proceed the sear number of the patient document. ⁴ Kind of document by the opporate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English targuages brankation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor Argen		ta, et al.		
Art Unit		3733		
Examiner Name PHIL		OGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	7 and 1.98 to	make the	appropriate:	selection(s	s):
---------------	----------	---------------	----------	--------------	-------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

•			
Signature	/Niels Haurr/	Date (YYYY-MM-DD)	2007-04-19
Name/Print	Niels Haun	Registration Number	48.488

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.